Update from Lexeo Therapeutics
In a press release today, June 15, 2026, Lexeo Therapeutics announced that they had finalized the SUNRISE-FA 2 pivotal trial protocol and statistical analysis plan (SAP) intended to provide clinical evidence to support the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for gene therapy candidate LX2006 under the accelerated approval pathway in 2028.
SUNRISE-FA 2 will be open to individuals living with Friedreich’s ataxia and heart muscle disease (cardiomyopathy). To stay informed, join the early notification list for upcoming SUNRISE-FA 2 updates and details here.